Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

Medtronic has reported late-breaking data from the Evolut Low Risk Trial’s five-year outcomes of the Evolut TAVR system.

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

A device designed to remove embolic material-fragments of tissue that can be released into the bloodstream during ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...